De-immunization Platform

About Equaly

Equaly is an early-stage biotech leveraging a groundbreaking platform that targets antigen-specific innate immune cells to modulate immune responses. This approach has the potential to create novel vaccines, reduce immunogenicity of biological drugs, and develop curative therapies for autoimmune diseases. As a private, pre-revenue company likely in the pre-clinical stage, Equaly is positioned as a pioneer in a nascent field, seeking partnerships to advance its platform toward therapeutic applications.

Therapeutic Areas